Abràmoff Michael D, Tarver Michelle E, Loyo-Berrios Nilsa, Trujillo Sylvia, Char Danton, Obermeyer Ziad, Eydelman Malvina B, Maisel William H
Departments of Ophthalmology and Visual Sciences, and Electrical and Computer Engineering, University of Iowa, Iowa City, IA, USA.
Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.
NPJ Digit Med. 2023 Sep 12;6(1):170. doi: 10.1038/s41746-023-00913-9.
Health equity is a primary goal of healthcare stakeholders: patients and their advocacy groups, clinicians, other providers and their professional societies, bioethicists, payors and value based care organizations, regulatory agencies, legislators, and creators of artificial intelligence/machine learning (AI/ML)-enabled medical devices. Lack of equitable access to diagnosis and treatment may be improved through new digital health technologies, especially AI/ML, but these may also exacerbate disparities, depending on how bias is addressed. We propose an expanded Total Product Lifecycle (TPLC) framework for healthcare AI/ML, describing the sources and impacts of undesirable bias in AI/ML systems in each phase, how these can be analyzed using appropriate metrics, and how they can be potentially mitigated. The goal of these "Considerations" is to educate stakeholders on how potential AI/ML bias may impact healthcare outcomes and how to identify and mitigate inequities; to initiate a discussion between stakeholders on these issues, in order to ensure health equity along the expanded AI/ML TPLC framework, and ultimately, better health outcomes for all.
健康公平是医疗保健利益相关者的首要目标,这些利益相关者包括患者及其倡导团体、临床医生、其他医疗服务提供者及其专业协会、生物伦理学家、支付方和基于价值的医疗保健组织、监管机构、立法者以及人工智能/机器学习(AI/ML)驱动的医疗设备制造商。新的数字健康技术,尤其是AI/ML,可能会改善诊断和治疗方面公平性不足的问题,但这也可能加剧差异,具体取决于如何处理偏差。我们为医疗保健AI/ML提出了一个扩展的全产品生命周期(TPLC)框架,描述了AI/ML系统在每个阶段中不良偏差的来源和影响、如何使用适当的指标对其进行分析,以及如何对其进行潜在的缓解。这些“考量”的目标是让利益相关者了解潜在的AI/ML偏差可能如何影响医疗保健结果,以及如何识别和减轻不公平现象;在利益相关者之间就这些问题展开讨论,以确保在扩展的AI/ML TPLC框架内实现健康公平,并最终为所有人带来更好的健康结果。